GlassScriptPhysician profile
Steven J Shechtman
NPI 1467717819
$5,597.99
in general payments reported to CMS, 2019-2025
35 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $156 · 2021: $403 · 2022: $878 · 2023: $1,060 · 2024: $1,576 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,013.09 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $683.59 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $619.10 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $530.04 | 2022-2025 | |
| Abbvie INC. | $378.53 | 2023-2025 | Ubrelvy |
| Abbott Laboratories | $276.88 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $220.05 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $216.62 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $194.53 | 2019-2023 | |
| Amgen INC. | $170.61 | 2021-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.15 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $103.92 | 2022-2024 | |
| Pfizer INC. | $100.01 | 2021-2025 | |
| Renalytix Ai, INC. | $96.49 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Dexcom, INC. | $90.63 | 2023-2024 | Dexcom G6 Transmitter |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shechtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.